Evaluating the effect of cladribine on marmoset B- and T-cell proliferation and survival

**Authors:** Yolanda Kap¹, Ursula Boschert², Bert t’Hart¹³

¹Biomedical Primate Research Center, Department of Immunobiology, Rijswijk, The Netherlands; ²EMD Serono Research & Development Institute Inc., Billerica, MA, United States; ³University Groningen, University Medical Center, Department of Neuroscience, Groningen, The Netherlands

**Short title to be displayed on app:** Effect of cladribine on marmoset B- & T-cells

**Background:** Translational experimental autoimmune encephalomyelitis (EAE) marmoset models have been used to assess peripheral and central activities of B-/T-cell-targeting multiple sclerosis drugs, without rodent species cross-reactivity. Here we present the feasibility of using an EAE marmoset model to assess selective depletion of lymphocyte subsets in blood, lymphoid organs and central nervous system following cladribine exposure. This study assessed cladribine’s effect on marmoset lymphocyte survival and proliferation *in vitro* and deoxycytidine (dCTP) levels in marmoset blood.

**Methods:** Following exposure to cladribine (1nM-100µM), *in vitro* proliferation and survival of naïve and activated (concanavalin A [ConA], phytohemagglutinin, MOG34-56, recombinant hMOG) peripheral blood mononuclear cells (PBMC), spleen/lymph nodes mononuclear cells and Epstein-Barr virus (EBV)-infected B-cells were assessed. Cells were cultured for 24, 48 or 72 hours before lymphocyte proliferation and survival analysis. Marmoset dCTP levels were measured by reverse-phase chromatography.

**Results:** Naïve and mitogen-stimulated (phytohemagglutinin/ConA) PBMC demonstrated dose-dependent declines in proliferation (~40% for cladribine 1µM/72h; 100% for 10µM/72h). No difference in efficacy was seen between naive versus stimulated cells. CD20⁺ B-cells were more sensitive to cladribine than CD3⁺ T-cells in the survival assay. Analysis of MOG34-56 and MOG protein re-stimulated spleen/lymph node mononuclear cells from EAE marmosets confirmed a dose-dependent effect of cladribine after antigen stimulation (100nM-500nM). EBV-infected B-cells demonstrated reductions in proliferation with cladribine (~60-100% inhibition at 1-5µM/72h). EBV-infected B-cell survival was unaffected by cladribine. Low dCTP concentrations were detectable in marmoset blood.

**Conclusions:** Cladribine concentrations as low as 1µM can inhibit proliferation of naïve or activated PBMC. B-cells were more sensitive than T-cells to cladribine-induced cell death. Cladribine inhibited proliferation and survival of marmoset EAE spleen/lymph node mononuclear cells after antigen re-stimulation and inhibited proliferation, but not survival, of EBV-infected marmoset B-cells.

**Disclosures:** This study was sponsored by EMD Serono Inc, a business of Merck KGaA, Darmstadt, Germany (in the USA), and Merck Serono SA, Geneva, an affiliate of Merck KGaA Darmstadt, Germany (ROW).
Author disclosures:

**YK** does not declare any conflicts of interest

**UB** is an employee of EMD Serono Research & Development Institute Inc., a business of Merck KGaA, Darmstadt, Germany

**BTH** does not declare any conflicts of interest